Kornimate/medical-research-clean huggingface dataset:
effects of transcutaneous spinal direct current stimulation in incomplete spinal cord injury

Conditions: Incomplete Spinal Cord Injury

Summary: the purpose of the study is to investigate the effects of a novel therapeutic approach with transcutaneous spinal direct current stimulation (tsdcs) to promote functional recovery and spasticity in chronic spinal cord injury (sci).

the purpose of the study is to investigate the effects of a novel therapeutic approach to promote functional recovery and spasticity in chronic sci. the tsdcs effect on neuro-physiological measures such as h reflex and somatosensory evoked potential (ssep) wiil be evaluated in subjects with sci. this incremental, design will allow the establishment of strong electrophysiological data prior to rapid clinical translation of the findings about this promising, early-stage technique. the central hypothesis is twofold: 1) active tsdcs will lead to a change in hmax/m max ratio than sham tsdcs, in a polarity dependent manner; and 2) active tsdcs will lead to a change in ssep amplitude and latency, in a polarity dependent manner.

Eligibility criteria:
inclusion criteria: * providing written informed consent prior to any study related procedures * 18-65 years of age * motor incomplete sci classified as b, c or d by the american spinal injury association impairment scale (ais) * traumatic lesion at or above t8-t9 neurological level * body mass index ≤ 30 (in order to facilitate reliable location of body landmarks guiding stimulation); * chronic sci (time since injury\>6 months) exclusion criteria: * unstable cardiopulmonary conditions * history of seizure, head injury with loss of consciousness, severe alcohol or drug abuse, and/or psychiatric illness * any joint contracture or severe spasticity, as measured by a modified ashworth score 4 * subject who cannot provide self-transportation to the study location * cardiac or neural pacemakers * pregnancy * lower motor neuron injury (eg: peripheral neuropathy, cauda equina syndrome) * uncontrolled diabetes with hba1c\>7 * history of severe autonomic dysreflexia * no planned alteration in therapy or medication for muscle tone during the course of the study(no botulinum toxin injections in last 3 months, no phenol injections in last 6 months, intrathecal baclofen pump dose stable for past 3 months, etc) * conditions for e.g., severe arthritis, extreme shoulder pain that would interfere with valid administration of the measures or with interpreting motor testing; * no contraindications to tsdcs * ferromagnetic material in the brain or in the spine (except for titanium used in segmental)

Keywords: incomplete sci
clearing alzheimer's disease molecular pathology without medications

Conditions: Alzheimer Disease; Amyloid Plaque; Amyloidosis

Summary: according to the most popular pathophysiological models of alzheimer's disease, the amyloid hypothesis, amyloid deposition is the causative event triggering a chain of other downstream events which finally lead to alzheimer's disease and dementia. in mouse models of alzheimer's disease, 40 hz multi-sensory (auditory and visual) stimulation was able to reduce the number and size of amyloid plaques throughout cortex and improve cognitive performance. the primary objective of this study is to assess whether an intervention consisting of 40 hz multi-sensory (auditory and visual) stimulation is able to reduce the amyloid load in non-demented amyloid-positive individuals. as secondary objectives, the investigators will assess whether such intervention is able to: * improve the brain electrical activity, * improve or slow down the worsening of alzheimer's blood-based biomarkers, * improve or slow down the worsening of cognition.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature (appendix informed consent form), * age 40-80, * ≥5 years of education, * previous evidence of brain amyloidosis (assessed by pet, csf, or blood-based biomarkers). exclusion criteria: * history of epilepsy; * clinically relevant visual or auditory diseases/deficits; * clinical diagnosis of dementia; * contraindication to amyloid-pet; * inability to undergo the procedures of the study, e.g. severe behavioral disturbances; * severe diseases: 1. malignant neoplasm within 5 years, 2. life threatening diseases, 3. severe systemic diseases (e.g. kidney insufficiency, cardiac insufficiency, decompensated diabetes, decompensated metabolic diseases, decompensated hypothyroidism, uncontrolled autoimmune diseases); * the participation to a clinical trial involving potential alzheimer's disease modifying therapies; * documented pregnancy or intention to become pregnant during the course of the study or breast feeding.
safety and immune response to a multi-component immune based therapy (mkc1106-pp) for patients with advanced cancer.

Conditions: Ovarian; Melanoma; Renal; Prostate; Colorectal; Endometrial Carcinoma; Cervical Carcinoma; Testicular Cancer; Thyroid Cancer; Small Cell Lung Carcinoma; Mesothelioma; Breast Carcinoma; Esophageal Carcinoma; Gastric Cancer; Pancreatic Carcinoma; Neuroendocrine Cancer; Liver Cancer; Gallbladder Cancer; Biliary Tract Cancer; Anal Carcinoma; Bone Sarcomas; Soft Tissue Sarcomas; Carcinoma of Unknown Origin, Primary

Summary: the present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.

the majority of tumors are ignored by the immune system and it was thought for a long time that tumor antigens did not exist. however, recently a number of tumor antigens have been described. these antigens reside on cancer cells and can be recognized by specific t-cells which can ultimately attack and destroy the tumor.

Eligibility criteria:
inclusion criteria: 18 years of age or older advanced, refractory solid malignancy that is histologically proven measurable disease ecog performance status of 0, 1 or 2 adequate bone marrow reserve as evidenced by a absolute neutrophil count (anc) = 1,500/microl; platelet count = 100,000/microl adequate renal and hepatic function as evidenced by a serum creatinine = 1.5 mg/dl; serum total bilirubin = 2.0 mg/dl; alkaline phosphatase = 3x the uln for the reference lab (= 5 the uln for the reference lab for subjects with known hepatic metastases); sgot/sgpt = 3x the uln for the reference lab (= 5 the uln for the reference lab for subjects with known hepatic metastases) exclusion criteria: symptomatic central nervous system (cns) metastases any autoimmune disorder positive hiv, hepatitis b or hepatitis c antibody test any allogeneic transplant congestive heart failure affected inguinal lymph nodes (metastatic process) or lack inguinal lymph nodes (resection)

Keywords: cancer vaccine
comparative study between cryoablation and radiofrequency ablation in the treatment of supraventricular tachycardia

Conditions: Supraventricular Tachycardia; Atrioventricular Nodal Reentrant Tachycardia

Summary: the purpose of this study is to compare the safety and effectiveness of cryoablation and radiofrequency ablation in the treatment of the commonest kind of supraventricular tachycardia, namely atrioventricular nodal reentrant tachycardia. the study hypothesis is that cryoablation is non-inferior to radiofrequency.


Eligibility criteria:
inclusion criteria: * patients who are referred for catheter ablation of supraventricular tachycardia and diagnosis of avnrt is made by cardiac electrophysiology study exclusion criteria: 1. patients who aged less than 18 or over 80. 2. patients who are pregnant. 3. patients who cannot give informed consent. 4. patients who are judged to have severe mental impairment and cannot report symptoms of palpitation during follow-up. 5. patients who had previous avnrt ablation before. 6. patients who have comorbid congenital heart disease.
mixed reality technique combined with 3d printing navigational template for localizing pulmonary nodules

Conditions: Video-assisted Thoracic Surgery; Lung Cancer; Pulmonary Nodule, Solitary; Pulmonary Nodule, Multiple

Summary: this study evaluates the viability and accuracy of preoperative mixed reality technique combined with three-dimensional printing navigational template guided localizing pulmonary small nodules.

pulmonary wedge resection is one of the most common types of operations performed by thoracic surgeons, especially given that more and more patients with ground glass nodules are being detected recently. one of the most significant current discussion concerning wedge resection is nodule localization. at present, a commonly used localization method is the ct-guided percutaneous lung puncture methylene blue staining marker localization, but this method has two main disadvantages: 1. the methylene blue dye is easy to spread, affecting the intraoperative judgment of nodule position by surgeon; 2. patients often suffer additional ct radiation. mixed reality (mr) technique aims to enhance the simple self-visual effect and facilitate visualization of the surrounding environment in any situation. the three-dimensional model can be visualized by mr technique through mr glasses. investigators project a three-dimensional reconstructed image of the patient's chest through mr glasses, then overlay the virtual chest with the actual chest, and then use this as a guide for percutaneous lung puncture localization. at the same time, investigators design an three-dimensional printing navigational template based on the 3d reconstruction model and place it on the surface of the body to help to guide the localization. this study is designed to evaluates the viability and accuracy of preoperative mixed reality technique combined with 3d printing navigational template guided localizing pulmonary nodules.

Eligibility criteria:
inclusion criteria: * a maximum target lung nodule (one or more) diameter ≤20 mm * a target nodule ctr \ 10 mm if the target nodule ctr was \>0·25. * plan to perform vats lung wedge resection exclusion criteria: * inability to comply with research protocols or research procedures * any unstable systemic disease (including active infections, uncontrolled high blood pressure, unstable angina, angina pectoris that has started within the last 3 months, congestive heart failure (≥ new york heart association \[nyha\] level ii ), cardiac infarction (6 months before enrollment), severe arrhythmia requiring medication, liver, kidney or metabolic disease * active bleeding; inability to withstand lying flat; inability to cooperate through breathing during puncture * pregnant or lactating women * other circumstances that the investigator believes are not suitable for enrollment

Keywords: pulmonary nodule localization three-dimensional printing mixed reality
study of abiraterone acetate in subjects with metastatic castration resistant prostate cancer

Conditions: Metastatic Castration Resistant Prostate Cancer

Summary: abiraterone acetate is an orally effective cyp17 inhibitor, which is metabolized into abiraterone in the body, and its inhibitory activity against cyp17 is 10-30 times that of ketoconazole. clinical studies have shown that abiraterone acetate can significantly reduce the level of prostate specific antigen (psa) in pca patients, and help to reduce tumors, extending the lifespan of patients with advanced pca for several years, and the toxicity is acceptable.


Eligibility criteria:
inclusion criteria: - 1.18 years and older, eastern cooperative oncology group (ecog) performance status of 0 to 1, life expectancy ≥ 6 months. 2. prostate cancer. 3. serum testosterone \<50 ng/dl (or 1.7 nmol/l). 4. prostate cancer progression or lesion metastasis. 5. restriction of antiandrogen therapy. 6. restriction of radiation therapy. 7. the treatment period of ketoconazole for prostate cancer was not exceed 7 days. 8. has not used opioid analgesics and azole drugs within 4 weeks before the first dose. 9. question 3 of the concise pain questionnaire (bpi-sf) scored from 0-3 points. 10. adequate laboratory indicators. 11. must be able to swallow tablets. 12. no pregnant or breastfeeding women, and a negative pregnancy test. 13. understood and signed an informed consent form. exclusion criteria: 1. prostate pathology results are neuroendocrine prostate cancer. 2. has received cytotoxic chemotherapy or biological therapy for metastatic castration resistant prostate cancer. 3. has contraindications to the use of prednisone. 4. a chronic disease that exceeds the prednisone dose in the study. 5. uncontrolled high blood pressure. 6. active or symptomatic viral hepatitis or other chronic liver disease. 7. visceral metastasis or brain metastasis. 8. pituitary or adrenal dysfunction. 9. active autoimmune diseases require the use of hormone therapy. 10. clinically significant heart disease. 11. participated in other clinical trials within 4 weeks.
a long-term study of tau-284 in pediatric patients with perennial allergic rhinitis

Conditions: Perennial Allergic Rhinitis

Summary: the objective of this study is to evaluate the long-term safety and efficacy of tau-284 (bepotastine besilate) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.

this is a multicenter,open-label, single-arm, uncontrolled study to evaluate the safety and efficacy of tau-284 (20 mg/day) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.

Eligibility criteria:
inclusion criteria: * patients aged between 7 and 15 years * patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic criteria * patients with a mean total score for the three major nasal symptoms \[sneezing, rhinorrhea, and nasal congestion\] of at least 3 on the basis of symptoms recorded in the nasal allergy diary during the observation period etc. exclusion criteria: * patients with vasomotor rhinitis or eosinophilic rhinitis * patients who have concurrent nasal disease that may affect the efficacy of tau-284 * patients with a history of any of the nasal surgical procedures * patients with current or previous history of drug allergy * patients who concurrently have renal function abnormalities that may cause safety problems etc.

Keywords: tau-284 bepotastine besilate histamine h1 receptor antagonists children
frequency of florid hyperthyroidism in patients taking iodinated salt

Conditions: Thyroid Dysfunction

Summary: thyroxin a vital hormone for life lot of body functions depend on proper functioning on pituitary thyroid axis. it exists in two major forms thyroxine (t4) and (t3) , each of them containing two iodine atoms on their inner (tyrosine) ring. synthesis of reasonable quantities of thyroid hormones requires adequate iodine intake to allow sufficient thyroidal uptake. the world health organization (who) recommendation for daily intake of iodine is 150 μg for children ≥12 years and adults, and 250 μg for pregnant and lactating women. however as we know optimum amount of iodine is required for normal pituitary thyroid axis like wise excessive intake may cause over functioning of axis hence over production of hormone that can be manifested both clinically and biochemically. this study is designed to observe the frequency of over hyperthyroidism in patients taking iodinated salt.

all patients presenting to endocrine clinic fulfilling inclusion and exclusion criteria will be recruited. they will be examined, their vitals including blood pressure pulse will be noted, thyroid clinical examination including eye signs and thyroid status will be done biochemical thyroid profile (tsh, free t3 \& free t4) will be noted in predesigned proforma. statistical analysis will be done ,after data is entered in statistical package for the social sciences (spss) version 25 .qualitative data will be presented as frequencies and percentages while quantitative data will be presented as mean medians and standard deviations.

Eligibility criteria:
inclusion criteria: 1. all patients presenting with biochemical hyperthyroidism 2. who are taking iodinated salt. 3. treatment naïve patients 4. both genders included 5. all patients who can give consent (18-60 years) exclusion criteria: 1) pregnant females 2) lactating mothers -

Keywords: thyroid iodine
minimally invasive robot-assisted and laparoscopic distal pancreatectomy in a pan-european registry

Conditions: Pancreas Disease

Summary: a planned analysis of outcomes among consecutive patients after midp from centers participating in the e-mips registry (2019-2021). main outcomes of interest were intraoperative events, major morbidity (clavien-dindo grade ≥3) and 30-day/in-hospital mortality.

the european registry for minimally invasive pancreatic surgery (e-mips) is an e-ahpba endorsed registry with the aim to monitor and safeguard the introduction of mips in europe. international multicenter audit-based studies focusing on outcomes of minimally invasive distal pancreatectomy (midp) are lacking. a planned analysis of outcomes among consecutive patients after midp from centers participating in the e-mips registry (2019-2021). main outcomes of interest were intraoperative events, major morbidity (clavien-dindo grade ≥3) and 30-day/in-hospital mortality.

Eligibility criteria:
inclusion criteria: data from all patients who underwent laparoscopic or robotic distal pancreatecromy between january 1st 2019 and december 31st 2021 were included exclusion criteria: other pancreatic procedures hybrid approaches (reconstruction phase open) procedures with insufficient baseline data / missing primary outcome data.
ifosfamide, doxorubicin and hypofractionated radiotherapy in neoadjuvant sarcoma treatment

Conditions: Sarcoma, Soft Tissue

Summary: prospective phase ii study. patients will be submitted to neoadjuvant chemotherapy (ct) and hypo fractionated radiotherapy (hrt) following by surgery. the remain viable cells will be analyzed and the patients whithin less than 30% will receive more 3 cycles of ct. all patients have deep high grade soft tissue sarcoma of extremity.

prospective phase ii non controlled study. staging: all patients will be submitted to a local magnetic resonance (mr), chest tomography (ct) and positron emission tomography-computed tomography (pet ct) previous to treatment. after the first ct cycle a new pet ct will be provided and one more at the end of the neoadjuvant treatment. chemotherapy: ct neoadjuvant: doxorubicin 75mg/m2 (cycles 1,2 and 3), and ifosfamide 9 g/m2 (cycles 1 and 3). radiotherapy: rt 25 gy / 5 x 500 cgy/day, beginning at cycle 2/day1. the surgery will be performed after 4-6 weeks from cycle 3. the remain of viable cells in surgical specimen will be analyzed and whether the the percentage value is less than 30% the patient will receive more 3 cycles of ct. a boost of rt is indicated if margins are considered r1 (microscopic positive margin).

Eligibility criteria:
inclusion criteria: * patients between 18-75 years old, with non metastatic deeply high grade soft tissue sarcoma of extremities. kps \> 70% (karnofsky performance status score) exclusion criteria: * patients with rhabdomyosarcoma, neuroendocrine tumor (pnet) and chondrosarcomas, or who have had received radiotherapy (rt) or chemotherapy (ct) previous, or recurrent tumors.

Keywords: sarcoma soft tissue sarcoma neoadjuvant chemotherapy neoadjuvant radiotherapy hypofractionated radiotherapy
5d lb ultrasound in determination of fetal weight in normal pregnancy : a pilot study

Conditions: Fetal Weight

Summary: 5d and 2d ultrasound will be done to normal pregnant women between 37 to 42 weeks gestation and fetal weight will be estimated using the hadlock formula using biometry measured by both ultrasounds. accuracy of 5d ultrasound in determining fetal weight will be determined.


Eligibility criteria:
inclusion criteria: * 20-40years * singleton pregnancy * normal pregnancy exclusion criteria: * intrauterine fetal death * multiple pregnancy * congenital anomaly * nonvisualized fetal parts by ultrasound * maternal medical disorders like diabetes and hypertension
msep: testing of physiological and immune-metabolic blood markers for maternal sepsis

Conditions: Sepsis; Maternal Sepsis; Maternal Sepsis During Labor; SIRS; Pregnancy; Infection

Summary: a prospective observational cohort study investigating physiological parameters vs biological markers of whole blood in septic and non-septic pregnant woman to predict systemic immune health

the altered physiology of pregnancy makes the signs and symptoms of sepsis less distinctive in the pregnant population. this can lead to both over treatment (with antibiotics) and late identification of sepsis. the progression of sepsis can be rapid in this population, resulting in severe morbidity and mortality. the mortality associated with sepsis in the general population is over 10%, while septic shock can increase this figure up to 30%. a study looking at maternal mortality due to sepsis recognised that the time from the onset of infection to death was less than 24 hours in 50% of patients. a review of the literature shows that half of the fatal cases of maternal sepsis could have been prevented with early detection of sepsis. the unmet need is therefore a diagnostic bedside tool that can be performed on women identified as high risk via physiological parameters. the tool needs to be quick and easy to use whilst accurate at diagnosing sepsis. study objectives to evaluate the effectiveness of physiological parameters in predicting maternal sepsis. to evaluate the effectiveness of alternative biomarkers in diagnosing maternal sepsis including a genomic sepsis-test. investigation of the systemic immune health of women undergoing an uncomplicated pregnancy and labour.

Eligibility criteria:
inclusion criteria: pregnant with viable pregnancy confirmed on ultrasound at dating scan and over 18 years of age able to provide informed consent (a translation service will be provided for women where english is not the first language); women recruited into cohort b will have deferred consent taken to avoid interference with clinical care. exclusion criteria: * pregnant woman under the age of 18 or wishing not to consent, withdrawing consent or lacking capacity.
phase 2 haplotype mismatched hsct in patients with hematological malignancies

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplasia; Chronic Myeloid Leukemia

Summary: the purpose of this study is to determine if haplotype-mismatched hsct is associated with an improvement in treatment-related mortality (trm) rate at 6 months.


Eligibility criteria:
inclusion criteria: * patients must have histologically documented aml, all, mds, cml, acute myeloid leukemia (aml) with one or more of the following criteria * cr 1 with poor risk features * cr 2, or higher order cr * acute lymphoblastic leukemia (all) with one of the following criteria * cr 1 with poor risk features * cr 2, or higher order cr * myelodysplasia, raeb i * donor has been identified * age ≤ 65 years. * performance status 0-1. exclusion criteria: * patients relapsing \<6 months after autologous sct are not eligible. * patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection. * non-pregnant and non-nursing